[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 7 of about 7
1. Coates RA: Lone atrial fibrillation: more than meets the eye. J Insur Med; 2004;36(1):88-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Doxorubicin has been used as a chemotherapeutic agent for over 30 years.
  • Its cardiac toxicity has been known for over 20 years.
  • In recent years, delayed-onset cardiac toxicity has been described as yet another cardiac complication of doxorubicin and other anthracyclines.
  • [MeSH-minor] Acute Disease. Adult. Cardiomyopathies / chemically induced. Electrocardiography. Humans. Insurance, Life. Male. Rhabdomyosarcoma / drug therapy

  • MedlinePlus Health Information. consumer health - Atrial Fibrillation.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15104034.001).
  • [ISSN] 0743-6661
  • [Journal-full-title] Journal of insurance medicine (New York, N.Y.)
  • [ISO-abbreviation] J Insur Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin
  •  go-up   go-down


2. Kushner BH, Kramer K, Meyers PA, Wollner N, Cheung NK: Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors. Med Pediatr Oncol; 2000 Nov;35(5):468-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The recommended dosages of topotecan and cyclophosphamide in combination for prior-treated patients-3.75 mg/m(2) and 1,250 mg/m(2) in children, 5 mg/m(2) and 600 mg/m(2) in adults, respectively-are well below those of each agent when used singly.
  • After HD-Cy/Topo, cardiac, renal, hepatic, and pulmonary function remained within the normal range.
  • Partial or minor responses were noted in neuroblastoma, desmoplastic small round-cell tumor, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Female. Humans. Male. Neuroblastoma / drug therapy. Pilot Projects. Sarcoma / drug therapy. Topotecan / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 11070479.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA61017; United States / NCI NIH HHS / CA / CA72868
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 7M7YKX2N15 / Topotecan; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


3. Semino A, Danova M, Perlini S, Palladini G, Riccardi A, Perfetti V: Unusual manifestations of disseminated neoplasia at presentation: right-sided heart failure due to a massive cardiac metastasis and autoimmune thrombocytopenia in pleomorphic rhabdomyosarcoma of the adult. Am J Clin Oncol; 2006 Feb;29(1):102-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual manifestations of disseminated neoplasia at presentation: right-sided heart failure due to a massive cardiac metastasis and autoimmune thrombocytopenia in pleomorphic rhabdomyosarcoma of the adult.
  • Although it is recognized that aggressive soft tissue sarcomas may give rise to cardiac metastases, these manifestations are usually late and clinically silent, being the prevailing finding in exceptional cases.
  • This report describes the occurrence of a massive cardiac metastasis at diagnosis of leg rhabdomyosarcoma in a middle-age adult.
  • This manifestation was the cause of rapidly progressive congestive heart failure and, together with the unusual occurrence of autoimmune thrombocytopenia, led to difficult patient care with a significantly negative influence on the outcome.
  • [MeSH-major] Heart Neoplasms / secondary. Rhabdomyosarcoma / secondary. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Comorbidity. Fatal Outcome. Heart Failure / etiology. Humans. Leg / pathology. Male. Purpura, Thrombocytopenic, Idiopathic / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462513.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Kasper B, Dietrich S, Mechtersheimer G, Ho AD, Egerer G: Large institutional experience with dose-intensive chemotherapy and stem cell support in the management of sarcoma patients. Oncology; 2007;73(1-2):58-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Apart from haematological complications, no WHO grade III-IV complications were observed.
  • One patient died due to cardiac arrest after transplantation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy. Sarcoma / surgery. Stem Cell Transplantation
  • [MeSH-minor] Adult. Aged. Chondrosarcoma / drug therapy. Chondrosarcoma / surgery. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Leiomyosarcoma / drug therapy. Leiomyosarcoma / surgery. Liposarcoma / drug therapy. Liposarcoma / surgery. Male. Middle Aged. Osteosarcoma / drug therapy. Osteosarcoma / surgery. Retrospective Studies. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma / surgery. Sarcoma, Ewing / drug therapy. Sarcoma, Ewing / surgery. Sarcoma, Synovial / drug therapy. Sarcoma, Synovial / surgery

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] : (c) 2008 S. Karger AG, Basel
  • (PMID = 18334832.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


5. Wang Q, Fang WH, Krupinski J, Kumar S, Slevin M, Kumar P: Pax genes in embryogenesis and oncogenesis. J Cell Mol Med; 2008 Dec;12(6A):2281-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Splotch phenotype in mouse exhibits defects in neural crest derivatives such as, pigment cells, sympathetic ganglia and cardiac neural crest-derived structures.
  • In particular, PAX3 is involved in rhabdomyosarcoma and tumours of neural crest origin, including melanoma and neuroblastoma.
  • [MeSH-minor] Alternative Splicing. Animals. Genetic Therapy. Humans. Melanocytes / cytology. Melanocytes / metabolism. Melanoma / etiology. Melanoma / genetics. Mice. Models, Genetic. Muscle Development / genetics. Neuroblastoma / etiology. Neuroblastoma / genetics. Neurogenesis / genetics. Oncogenes. Rhabdomyosarcoma / etiology. Rhabdomyosarcoma / genetics

  • Genetics Home Reference. consumer health - PAX3 gene.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18627422.001).
  • [ISSN] 1582-1838
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Paired Box Transcription Factors
  • [Number-of-references] 138
  • [Other-IDs] NLM/ PMC4514106
  •  go-up   go-down


6. Bergeron C, Thiesse P, Rey A, Orbach D, Boutard P, Thomas C, Schmitt C, Scopinaro MJ, Bernard F, Stevens M, Oberlin O: Revisiting the role of doxorubicin in the treatment of rhabdomyosarcoma: an up-front window study in newly diagnosed children with high-risk metastatic disease. Eur J Cancer; 2008 Feb;44(3):427-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Revisiting the role of doxorubicin in the treatment of rhabdomyosarcoma: an up-front window study in newly diagnosed children with high-risk metastatic disease.
  • PURPOSE: Many cooperative groups have reported on the chemo-sensitivity of rhabdomyosarcoma (RMS).
  • PATIENTS AND METHODS: Patients younger than 18 years of age (>6 months) with newly diagnosed, histologically confirmed high-risk metastatic RMS were required to have measurable disease, to have undergone no prior chemotherapy or radiation therapy and to have normal liver, renal and cardiac function before treatment.
  • Response to therapy was assessed by diagnostic imaging after the second course.
  • Median age at diagnosis was 9.8 years (range from 2 to 16).
  • The rates of CR and PR were 5% [95% CI, 0-14%] and 60% [95% CI, 39-81%], respectively.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Doxorubicin / administration & dosage. Rhabdomyosarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Analysis of Variance. Child. Child, Preschool. Drug Administration Schedule. Female. Humans. Infusions, Intravenous. Male. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18215514.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 80168379AG / Doxorubicin
  •  go-up   go-down


7. van Dalen EC, Raphaël MF, Caron HN, Kremer LC: Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer. Cochrane Database Syst Rev; 2009;(1):CD006647
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SELECTION CRITERIA: Randomised controlled trials (RCTs) comparing treatment of any type of childhood cancer with and without anthracyclines and reporting outcomes concerning antitumour efficacy.
  • MAIN RESULTS: We identified RCTs for 5 types of tumour: acute lymphoblastic leukaemia (ALL) (n=3; 912 children), Wilms' tumour (n=1; 316 children), rhabdomyosarcoma/undifferentiated sarcoma (n=1; 413 children), Ewing's sarcoma (n=1; 94 children), and non-Hodgkin lymphoma (n=1; 284 children).
  • For both rhabdomyosarcoma/undifferentiated sarcoma and non-Hodgkin lymphoma no difference in antitumour efficacy between the treatment groups was identified.
  • None of the studies evaluated asymptomatic cardiac dysfunction.
  • For Wilms' tumour, rhabdomyosarcoma/undifferentiated sarcoma, Ewing's sarcoma, and non-Hodgkin lymphoma only 1 RCT was available and therefore, no definitive conclusions can be made about the antitumour efficacy of treatment with or without anthracyclines in these tumours.
  • [MeSH-major] Anthracyclines / therapeutic use. Antibiotics, Antineoplastic / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Bone Neoplasms / drug therapy. Child. Heart Diseases / chemically induced. Humans. Kidney Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Randomized Controlled Trials as Topic. Sarcoma / drug therapy. Wilms Tumor / drug therapy

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2011;(1):CD006647 [21249679.001]
  • (PMID = 19160293.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibiotics, Antineoplastic
  • [Number-of-references] 172
  •  go-up   go-down






Advertisement